TheEdgeResearch
Home / Stocks / GH

Guardant Health, Inc. (GH)

NASDAQ Healthcare Medical - Diagnostics & Research
$179.38 ▼ -2.03%
Market Cap
$24.07B
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Beta
1.58
52-Wk Range
55.38-183.51
CEO
Helmy Eltoukhy
Country
US
Currency
USD

Guardant Health, Inc. operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Palo Alto, CA, US. The stock last traded at $179.38, down 2.03% on the session, giving a market capitalisation of $24.07B. On trailing twelve-month figures it carries a trailing P/E of -51.40, a net margin of -38.3%. Its beta of 1.58 implies it has historically moved more than the broad market.

Valuation & profitability (TTM)
P/E
-51.40
Price / Sales
20.35
Price / Book
-106.30
EV / EBITDA
-60.11
Gross margin
65.0%
Operating margin
-39.7%
Net margin
-38.3%
Return on equity
Debt / equity
-7.61
Current ratio
4.03
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ Global Select
Employees
2,498
IPO date
2018-10-04
Headquarters
Palo Alto, CA, US
About Guardant Health, Inc.

Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.

Comparable companies

Guardant Health, Inc. is most often compared with the following Healthcare names:

ASNDBBIOEHCEXASICLRIONSQGENRVTYSOLVVTRS
More research on GH
GH technical analysis GH TheEdge Score Compare against peers
Open full interactive analysis & DCF →